Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB

Tuberculosis, Pulmonary Clinical Trial

Official title:

A Phase 2a/2b Study Evaluating Safety, Immunogenicity, and Therapeutic Efficacy of ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06205589
• Other study ID #: ACTG A5397
• Secondary ID: UM1AI068636
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: October 15, 2024
• Est. completion date: April 1, 2029

Study information

• Verified date: May 2024
• Source: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
• Contact: ACTG CT.gov Coordinator
• Phone: (301)628-3348
• Email: ACTGCT.gov[@]dlhcorp.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is being done to test an experimental study vaccine compared to a placebo. The experimental study vaccine is called ID93 + GLA-SE. ID93 + GLA-SE has been used in humans in research but has not been approved for use in medical care. This study will be the first to test ID93 + GLA-SE in people living with HIV (PLWH). The injections during the study will be given to different groups of participants while they are using standard TB treatment. One of the research questions is to understand the differences in immune system responses depending on the timing of giving the injections after people begin taking standard TB treatment. Researchers also want to continue to look at whether the study vaccine is safe when tested in a larger group of people, and if getting the study vaccine in addition to standard TB treatment can help to lower the number of poor TB outcomes that people might have.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 1500
• Est. completion date: April 1, 2029
• Est. primary completion date: April 1, 2029
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria Groups 1-5:

• Bacteriologically confirmed rifampicin-susceptible pulmonary TB using phenotypic drug susceptibility testing or a World Health Organization (WHO) approved molecular test.
• Documentation of HIV status as positive or negative by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit.
• For individuals with HIV, on locally approved HIV ART for at least 90 days prior to entry.
• For individuals with HIV, CD4+ cell count =250 cells/mm3 obtained within 90 days prior to entry at any network-approved non-US laboratory that is DAIDS IQA certified.
• For individuals with HIV, HIV-1 RNA below the limit of detection obtained within 90 days prior to entry by any network-approved laboratory outside the US that operates in accordance with Good Clinical Laboratory Practices (GCLP) and participates in appropriate external quality assurance programs.
• Laboratory values within the indicated ranges, obtained within 14 days prior to entry by any network-approved laboratory outside the US that operates in accordance with GCLP and participates in appropriate external quality assurance programs.
• Absolute neutrophil count (ANC) =800 cells/mm3
• Hemoglobin =8.5 g/dL for candidates assigned female sex at birth and >9.0 g/dL for candidates assigned male sex at birth
• Platelet count =100,000/mm3
• Serum creatinine =1.5 X upper limit of normal (ULN)
• AST (SGOT), ALT (SGPT), and alkaline phosphatase, =2.5 X ULN
• Total bilirubin =2 X ULN
• For candidates who are able to become pregnant, negative serum or urine pregnancy test at or within 7 days prior to entry by any network-approved laboratory or clinic outside the US that operates in accordance with GCLP and participates in appropriate external quality assurance programs.
• Candidates who are able to become pregnant must agree to use an adequate method of contraception (barrier methods or non-hormonal intrauterine device) or abstain from sexual activity that could lead to pregnancy from at least 21 days prior to the first scheduled vaccination through 90 days after last dose.
• Candidates assigned female sex at birth (AFAB) must agree to not seek pregnancy through alternative methods, such as oocyte retrieval, artificial insemination, or in vitro fertilization, from at least 21 days prior to the first scheduled vaccination through 90 days after last dose.
• For candidates who are not of child-bearing potential, acceptable documentation (written documentation or oral communication from a clinician or clinician's staff documented in source documents: physician report/letter, operative report or other source documentation in the candidate record, discharge summary, laboratory report, etc.) of hysterectomy and bilateral oophorectomy, tubal ligation, tubal micro-inserts, vasectomy, or menopause.
• Ability and willingness of candidate to provide informed consent.

Inclusion Criteria Groups 1 and 2 [Step 2]:

• Documented duration of local SOC TB treatment prior to entry into Step 2 (study entry) for i. Group 1 of between 113 and 127 days (i.e., approximately 4 months of TB treatment) ii. Group 2 of between 83 and 97 days (i.e., approximately 3 months of TB treatment)

Inclusion Criteria, Groups 3, 4, and 5 [Step 1]:

• Initiation of local SOC TB treatment within 7 days prior to entry into Step 1 (Study entry).

Exclusion Criteria Groups 1-5:

• Documented M.tb resistance to isoniazid.
• Breastfeeding.
• Any previous episode of TB treatment.
• TB treatment with a local non-standard first-line TB treatment regimen at time of enrollment.
• Receipt of any investigational drug or any investigational non-TB vaccine since start of TB treatment.
• Any prior receipt of any investigational TB vaccine.
• Known allergy or any hypersensitivity to any components of study product or their formulation or any vaccination.
• Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
• History of moderate to serious autoimmune disease requiring immunosuppressive therapy.
• Receipt of immunosuppressive medications (except as noted below) from start of TB treatment.
• Corticosteroid nasal spray
• Inhaled corticosteroids
• Topical corticosteroids for mild, uncomplicated dermatologic condition
• A single course of oral/parenteral prednisone or equivalent at doses <60 mg/day and for <11 days with completion at least 30 days prior to entry.
• Receipt of Emergency Use Authorization (EUA)/Emergency Use Listing (EUL) or licensed live attenuated vaccines (e.g., measles, mumps, and rubella [MMR], oral polio vaccine [OPV], varicella, yellow fever, live attenuated influenza vaccine, live attenuated COVID-19 vaccine) within 30 days prior to entry.
• Receipt of any EUA/EUL or licensed vaccines that are not live attenuated vaccines (e.g., tetanus, pneumococcal, Hepatitis A or B, not live attenuated COVID-19 vaccine) within 14 days prior to entry.
• Receipt of immunoglobulin or blood-derived products within 90 days prior to entry.
• History of angioedema, or anaphylaxis, except as noted.
• History of generalized urticaria within past 5 years.
• Malignancy, except as noted.
• Daily (current) use of a short-acting rescue inhaler (e.g., a beta 2 agonist).
• Within the previous year, exacerbation of asthma symptoms requiring emergency care, urgent care, hospitalization, or intubation.
• Uncontrolled diabetes mellitus type 1 or type 2, defined as Hemoglobin A1c (HbA1C) >7%.
• Bleeding disorder (e.g., factor deficiency, coagulopathy, platelet disorder requiring special precautions).
• Seizure disorder, including either of the following within the previous 3 years:
• Seizure(s)
• Use of medications to prevent or treat seizure(s)
• Acute or serious illness, including COVID-19, requiring systemic treatment and/or hospitalization from start of TB treatment, other than for pulmonary TB.
• Documentation of clinically significant (as judged by the site investigator) active infections (including HIV-related opportunistic infections) other than TB and HIV requiring treatment within 30 days prior to entry.
• Evidence of clinically significant disease (as judged by the site investigator) or any other abnormalities (other than the indication being studied) that would interfere with study product, procedures, or interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
• Suspected or documented TB involving the central nervous system, renal TB or TB pericarditis, or current extrapulmonary TB involving other organ systems that might interfere with study product or procedures, as judged by the site investigator.
• Contraindication to intramuscular injection in both deltoids.

Related Conditions & MeSH terms

• Tuberculosis
• Tuberculosis, Pulmonary

Intervention

Biological:
• ID93 + GLA-SE vaccine
At Step 2 entry, participants will receive one 0.5 mL injection of ID93 + GLA-SE administered intramuscularly (IM) at the Step 2, Day 0 visit and at the Step 2, Day 60 visit per the dosing schedule within the respective group/arm.
• Placebo vaccine
At Step 2 entry, participants will receive one placebo injection (sodium Chloride, 0.9%) administered intramuscularly (IM) at the Step 2, Day 0 visit and at the Step 2, Day 60 visit per the dosing schedule within the respective group/arm.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	National Institute of Allergy and Infectious Diseases (NIAID)

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety (Phase 2a and Phase 2b): Vaccine-related serious adverse event (SAE)	Vaccine-related serious adverse event (SAE) at any time after first dose of ID93 + GLA-SE. The relationship to study product will be determined by the site investigator and assessed as "related" or "unrelated". Only SAEs reported as "related" will be included in this outcome measure.	From Step 2, Day 0 through to 420, 450, 480 or 510 days (approximately 18 months after start of SOC treatment)
Primary	Safety (Phase 2a and Phase 2b): Grade =3 vaccine-related unsolicited adverse event (AE)	Grade =3 vaccine-related unsolicited adverse event (AE) within 28 days after either dose of study product. An unsolicited AE is defined as an AE other than a local or systemic reactogenicity AE. The relationship to study product will be determined by the site investigator and assessed as "related" or "unrelated." Only unsolicited AEs reported as "related" will be included in this outcome measure.	Within 28 days from Step 2, Day 0 or Step 2, Day 60
Primary	Safety (Phase 2a and Phase 2b): Grade =3 local or systemic reactogenicity AE	o Systemic symptoms include increased body temperature, malaise and/or fatigue, myalgia, headache, chills, arthralgia, nausea, and vomiting. Local symptoms include pain and/or tenderness proximal to the injection site.	Within 7 days from Step 2, Day 0 or Step 2, Day 60
Primary	Cellular immunogenicity (Phase 2a and Phase 2b): ID93-specific CD4+ T cell response relative to the negative control stimulation	ID93-specific CD4+ T cell response relative to the negative control stimulation (ICS response criteria: MIMOSA method) at 2 weeks post second dose of study product. CD4+ T cell response measured by ICS with magnitude indicated by cells expressing 2 of IFN?/IL2/TNFa/CD154. MIMOSA detects responses compared to the negative control. This will be evaluated as a binary outcome (i.e., response or no response).	Step 2, Day 75
Primary	Cellular immunogenicity (Phase 2a and Phase 2b): ID93-specific CD4+ T cell response relative to the negative control stimulation and relative to the pre-vaccine response	ID93-specific CD4+ T cell response relative to the negative control stimulation and relative to the pre-vaccine response (ICS response criteria: MIMOSA2 method) at 2 weeks post second dose of study product. CD4+ T cell response measured by ICS with magnitude indicated by cells expressing 2 of IFN?/IL2/TNFa/CD154. MIMOSA2 detects responses compared to the negative control stimulation and the pre-vaccine response. This will be evaluated as a binary outcome (i.e., response or no response).	Step 2, Day 75
Primary	Cellular immunogenicity (Phase 2a and Phase 2b): ID93-specific CD4+ T cell response magnitude relative to the negative control stimulation	ID93-specific CD4+ T cell response magnitude relative to the negative control stimulation at 2 weeks post second dose of study product. CD4+ T cell response measured by ICS with magnitude indicated by cells expressing 2 of IFN?/IL2/TNFa/CD154. This will be evaluated as a continuous outcome.	Step 2, Day 75
Primary	Efficacy (Phase 2b): Bacteriologically confirmed TB-related unfavorable outcome (treatment failure, TB recurrence, or death due to TB)	Bacteriologically confirmed TB-related unfavorable outcome (treatment failure, TB recurrence, or death due to TB) after receiving the first dose of study product (ID93 + GLA-SE or placebo). Bacteriological confirmation will be based on culture results from solid media and liquid media that are positive for M. tuberculosis. Culture results from the study or from outside the study (e.g., the local TB program) are acceptable.	Step 2, Day 0 to 420, 450, 480 or 510 days (approximately 18 months after start of SOC treatment)
Secondary	Efficacy (Phase 2a and 2b): Proportion of participants with quantifiable RS ratio	RS ratio will be evaluated as a binary outcome (quantifiable or not quantifiable)	Step 2, Days 60, 90, 120, and 150 in Groups 1, 2, 3 (and 5), and 4 (and 5), respectively (approximately 6 months after start of SOC treatment)
Secondary	Cellular immunogenicity (Phase 2a): ID93-specific CD4+ T cell response through 12 months post second dose of vaccination	Measured by ICS and flow cytometry. CD4+ T-cell response magnitude indicated by cells expressing 2 of IFN?/IL2/TNFa/CD154. This will be evaluated as both a binary outcome (response or no response) and as a continuous outcome.	Step 2, Days 0, 15, 60, 75, 120 (Group 3 only), 150 (Group 4 only), 240, 300 (Group 3 only), 330 (Group 4 only) and 420 (Group 2 will be evaluated at Day 450 rather than 420)
Secondary	Humoral immunogenicity (Phase 2a): ID93-specific IgG response rate	BAMA response criteria: MFI* >3 x [MFI* at pre-vaccine] and MFI* >100. This will be evaluated as both a binary outcome (i.e., response or no response) and as a continuous outcome.	Step 2, Days 0, 15, 60, 75, 120 (Group 3 only), 150 (Group 4 only), 240, 300 (Group 3 only), 330 (Group 4 only) and 420 (Group 2 will be evaluated at Day 450 rather than 420)
Secondary	Immunogenicity (Phase 2a): Differential leukocyte count and immunophenotype	Evaluated in cryopreserved ex vivo whole blood by flow cytometry in Groups 1-4	Step 2, Days 0, 1, 15, and 75
Secondary	Immunogenicity (Phase 2a): Measurement of soluble proinflammatory mediators	Evaluated in serum in Groups 1-4	Step 2, Days 0, 1, 15, and 75